FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995524648> ?p ?o ?g. }

• W2995524648 abstract "# Background Visceral leishmaniasis is found primarily in developing countries and is a neglected tropical disease that causes approximately 300,000 new cases and 20,000 deaths annually and is often fatal if untreated. Monotherapy with pentavalent antimonials (SSG or MA) is a second-line treatment option in many endemic areas. This meta-analysis provides regional and national analyses of the proportions of antimonial treatment failures at the end-of-treatment and at follow-up according to the drug used. # Methods This meta-analysis was conducted in accordance with the PRISMA guidelines. Studies were identified by systematic searches of five electronic databases. Studies in English that reported the outcomes of 10 or more patients treated according to the World Health Organization (WHO) pentavalent antimonial regimen (20 mg/kg/day for 28-30 days) were included. Random-effects meta-analyses and funnel plots were performed, and bias was assessed using tools from the Cochrane collaboration. # Results 33 articles were included in the final per protocol analyses, 16 from the Indian subcontinent (India and Nepal), 15 from East Africa and one from each of Iran and Turkey. Data were analysed by drug type regionally, nationally and temporally. Six-month follow-up data from 13 studies (n=797) on the Indian subcontinent gave a sodium stibogluconate (SSG) failure rate of 11.34% (95% confidence interval (CI)=7.05-16.48%). Nationally, the SSG failure rate across 11 studies from northern India greatly exceeded that identified from two Nepalese studies. Six-month follow-up data from three studies (n=638) from East Africa gave an SSG failure rate of 6.25% (95% CI=4.51-8.25%). End-of-SSG-treatment failure rates across the Indian subcontinent (n=1,135), northern India (n=990) and Nepal (n=145) were 39.82% (95% CI=31.67-48.27%), 45.21% (95% CI=39.31-51.17%) and 12.17% (95% CI=7.40-17.93%) respectively. A lower end-of-SSG-treatment failure rate was recorded in East Africa (n=53,335), 6.60% (95% CI=2.94-11.58%). No studies contained six-month follow-up data regarding meglumine antimoniate (MA), and only four studies (n=257) contained end-of-MA-treatment data with a failure rate of 5.01% (95% CI=2.70-7.98%). # Conclusions Sb(V) remains an important second-line therapy in many areas. Knowledge of failure rates can inform policy decisions at all levels. The findings of this study are most applicable to SSG therapy, confirm the known patterns of resistance and reflect current policies." @default.
• W2995524648 created "2019-12-26" @default.
• W2995524648 creator A5006757242 @default.
• W2995524648 creator A5019775047 @default.
• W2995524648 creator A5069862202 @default.
• W2995524648 date "2019-12-09" @default.
• W2995524648 modified "2023-10-17" @default.
• W2995524648 title "Treatment failure of pentavalent antimonial therapy for human visceral leishmaniasis: a meta-analysis" @default.
• W2995524648 cites W1561556558 @default.
• W2995524648 cites W1971247424 @default.
• W2995524648 cites W1975656524 @default.
• W2995524648 cites W1982520984 @default.
• W2995524648 cites W1997496547 @default.
• W2995524648 cites W2001692225 @default.
• W2995524648 cites W2008384755 @default.
• W2995524648 cites W2022956687 @default.
• W2995524648 cites W2034990066 @default.
• W2995524648 cites W2035978128 @default.
• W2995524648 cites W2036740 @default.
• W2995524648 cites W2038565126 @default.
• W2995524648 cites W2039812524 @default.
• W2995524648 cites W2042880168 @default.
• W2995524648 cites W2046144222 @default.
• W2995524648 cites W2048063935 @default.
• W2995524648 cites W2070844208 @default.
• W2995524648 cites W2075893576 @default.
• W2995524648 cites W2076026695 @default.
• W2995524648 cites W2082293404 @default.
• W2995524648 cites W2083215321 @default.
• W2995524648 cites W2086258935 @default.
• W2995524648 cites W2097202300 @default.
• W2995524648 cites W2099976976 @default.
• W2995524648 cites W2102273382 @default.
• W2995524648 cites W2103632818 @default.
• W2995524648 cites W2109788582 @default.
• W2995524648 cites W2111667824 @default.
• W2995524648 cites W2112156978 @default.
• W2995524648 cites W2119605658 @default.
• W2995524648 cites W2125435699 @default.
• W2995524648 cites W2125483721 @default.
• W2995524648 cites W2126171754 @default.
• W2995524648 cites W2127260998 @default.
• W2995524648 cites W2129359359 @default.
• W2995524648 cites W2136086972 @default.
• W2995524648 cites W2137600992 @default.
• W2995524648 cites W2147221460 @default.
• W2995524648 cites W2151324264 @default.
• W2995524648 cites W2157823046 @default.
• W2995524648 cites W2157865685 @default.
• W2995524648 cites W2158758064 @default.
• W2995524648 cites W2163971309 @default.
• W2995524648 cites W2463782514 @default.
• W2995524648 cites W2531269403 @default.
• W2995524648 cites W2550266174 @default.
• W2995524648 cites W2555473081 @default.
• W2995524648 cites W2573547936 @default.
• W2995524648 cites W2594995121 @default.
• W2995524648 cites W2732308772 @default.
• W2995524648 cites W2775643792 @default.
• W2995524648 cites W4235416610 @default.
• W2995524648 cites W4237895871 @default.
• W2995524648 doi "https://doi.org/10.29392/joghr.3.e2019048" @default.
• W2995524648 hasPublicationYear "2019" @default.
• W2995524648 type Work @default.
• W2995524648 sameAs 2995524648 @default.
• W2995524648 citedByCount "1" @default.
• W2995524648 countsByYear W29955246482022 @default.
• W2995524648 crossrefType "journal-article" @default.
• W2995524648 hasAuthorship W2995524648A5006757242 @default.
• W2995524648 hasAuthorship W2995524648A5019775047 @default.
• W2995524648 hasAuthorship W2995524648A5069862202 @default.
• W2995524648 hasBestOaLocation W29955246481 @default.
• W2995524648 hasConcept C126322002 @default.
• W2995524648 hasConcept C141071460 @default.
• W2995524648 hasConcept C195244886 @default.
• W2995524648 hasConcept C203014093 @default.
• W2995524648 hasConcept C2776555147 @default.
• W2995524648 hasConcept C2778689377 @default.
• W2995524648 hasConcept C2780122544 @default.
• W2995524648 hasConcept C2780423678 @default.
• W2995524648 hasConcept C2781413609 @default.
• W2995524648 hasConcept C2991810699 @default.
• W2995524648 hasConcept C44249647 @default.
• W2995524648 hasConcept C556039675 @default.
• W2995524648 hasConcept C71924100 @default.
• W2995524648 hasConcept C95190672 @default.
• W2995524648 hasConcept C95457728 @default.
• W2995524648 hasConceptScore W2995524648C126322002 @default.
• W2995524648 hasConceptScore W2995524648C141071460 @default.
• W2995524648 hasConceptScore W2995524648C195244886 @default.
• W2995524648 hasConceptScore W2995524648C203014093 @default.
• W2995524648 hasConceptScore W2995524648C2776555147 @default.
• W2995524648 hasConceptScore W2995524648C2778689377 @default.
• W2995524648 hasConceptScore W2995524648C2780122544 @default.
• W2995524648 hasConceptScore W2995524648C2780423678 @default.
• W2995524648 hasConceptScore W2995524648C2781413609 @default.
• W2995524648 hasConceptScore W2995524648C2991810699 @default.
• W2995524648 hasConceptScore W2995524648C44249647 @default.
• W2995524648 hasConceptScore W2995524648C556039675 @default.
• W2995524648 hasConceptScore W2995524648C71924100 @default.

• next